Does This Drug Maker For Hepatitis C Have More Upside?

When a drug maker reports curing 100 percent of study patients enrolled in a study, it is a reason for its stock to rally. Gilead Sciences (GILD) reported that all of its patients were cured from Hepatitis C after taking two Gilead drugs and a generically available pill.

Gilead is trading at a new high:

Anyone who missed the run-up and would want to participate in its rise should ask a few questions. First, investors need to scrutinize the study and evaluate the likelihood of the product being launched to market. Second, valuation still matters. Now that more enthusiasm is priced in the stock, shares could now be too expensive.

Using Kapitall Number Cruncher, the tool reports that Gilead has a Price of Profit of 19, a market capitalization of $57.6 billion, and a price to book ratio of 6.5x. Plotting Gilead in Kapitall’s “Compare Multiple Companies” launch tool, Gilead may be seen as having the second-largest market cap compared to its peers. Amgen and Abbott, who is Gilead’s closest competitor, has a bigger market cap:

Caution:

Gilead’s Hepatitis study had just 25 patients enrolled, which is statistically insignificant. The study also looked at data only four weeks after the treatment was completed. Regulators usually wait 12 or 24 weeks after the treatment to confirm a patient is cured.

Competition:

Abbott has a cocktail of a combination of 5 drugs for hepatitis treatment. Vertex (VRTX) and Merck (MRK) have treatments that have a cure rate of up to 75%, but the failure rate is 25%.

Brystol-Myers (BMY) had a drug in the works during the summer, but it failed because of safety issues. Another hepatitis drug was reportedly curing 94% of patients 12 weeks after they were treated. This is arguably a better statistic than that of Gilead’s study.

Final Words:

If Gilead confirms its solid results for Hepatitis C, the company’s shares will soar even higher. Investors who are cautious might want to wait for more data.

Business Section: Investing Ideas

Companies mentioned in this article are:

 

1. Gilead Sciences Inc. ( GILD, Earnings, Analysts, Financials): Engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Market cap at $56.56B, most recent closing price at $74.65.

 

2. Vertex Pharmaceuticals Incorporated ( VRTX, Earnings, Analysts, Financials): Engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide. Market cap at $8.67B, most recent closing price at $39.98.

 

3. Merck & Co. Inc. ( MRK, Earnings, Analysts, Financials): Provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. Market cap at $133.4B, most recent closing price at $43.88.

 

4. Bristol-Myers Squibb Company ( BMY, Earnings, Analysts, Financials): Develops, and delivers innovative medicines that help patients prevail over serious diseases. Market cap at $53.83B, most recent closing price at $32.61.

 

 

Related Articles in this Sector:

 

Written by Chris Lau

To interact and discuss these picks or picks of your own with users, attach your watch list or portfolio in a message to your friends on Kapitall. To connect with users on the  leaderboard: from  your tool bar, select  Get Connected  -> Top KaptallistsMembers on Kapitall earn free points, and even more points with every Kapitall Generation trade. These points may be redeemed at the Kapitall  store .

 

Analyze These Ideas: Getting Started

null

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says